Celsion Corp (CLSN) 3.20 $CLSN
Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Thu May 08, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2014 and provided an update on its development program for ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III program for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver
Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - Thu May 08, 3:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis
Celsion Corporation to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014
PR Newswire - Thu May 01, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss first quarter 2014 financial results at 11:00 a.m. EDT on Thursday, May 8, 2014. To participate in the call, interested parties may dial 1-888-523-1225 (Toll-Free/North America) or 1-719-325-2329 (International/Toll) and ask for the Celsion 1st Quarter 2014 Conference Call (Conference Code: 1639390) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014
PR Newswire - Thu Apr 24, 5:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review of the final study design of the Phase III OPTIMA Study, which both explore ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer, were presented at the 5th European Conference on Interventional Oncology (ECIO) on April 24, 2014 in Berlin, Germany. Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of the Diagnostic Imaging and Intervention at the Pisa University School of Medicine in Italy, former ECIO President, current Chairman of the World Conference on Interventional Oncology (WCIO) and Lead European Principal Investigator for Celsion's clinical studies of ThermoDox® plus RFA, presented the results and review as part of his Honorary Lecture presentation. The slide presentation will be on the Events and Presentations page on the Celsion website when available.
Celsion Announces ThermoDox® HCC Program to be discussed at the 2014 European Conference on Interventional Oncology in Berlin, Germany
PR Newswire - Thu Apr 10, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of the Diagnostic Imaging and Intervention at the Pisa University School of Medicine in Italy, former ECIO President, current Chairman of the World Conference on Interventional Oncology (WCIO) and Lead European Principal Investigator for Celsion's clinical studies of ThermoDox® plus radiofrequency ablation for the treatment of hepatocellular carcinoma (HCC) or primary liver cancer will, in conjunction with his Honorary Lecture presentation, review the final clinical trial results from the 701 patient HEAT Study post hoc analysis and the rationale for the final study design of the Phase III OPTIMA Study at the 5th European Conference on Interventional Oncology, which is being held April 23-26, 2014 in Berlin, Germany.
Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound
PR Newswire - Wed Apr 09, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that data supporting the development of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound (HIFU) were presented on April 5, 2014 at the 14th International Symposium on Therapeutic Ultrasound in Las Vegas, Nevada. In a presentation entitled "Combining Thermosensitive Liposomes with Ultrasound," Mark Dewhirst, D.V.M., Ph.D., the Gustavo S. Montana Professor of Radiation Oncology and Vice Director for Basic Science in the Duke Cancer Institute, presented data demonstrating the potential of ThermoDox plus HIFU to maximize drug delivery to the targeted tumor site. Celsion is exploring the potential of ThermoDox in combination with HIFU as a non-invasive treatment for a variety of cancers, including pancreatic cancer, Glioblastoma Multiforme (GBM), metastatic liver cancer, and breast cancer. Dr. Dewhirst's presentation is available on the Celsion website at www.celsion.com.
Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update
PR Newswire - Thu Mar 13, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
3 Stocks Under $10 Making Big Moves
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
PR Newswire - Thu Mar 06, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2013 financial results at 11:00 a.m. EST on Thursday, March 13, 2014. To participate in the call, interested parties may dial 1-888-572-7033 (Toll-Free/North America) or 1-719-325-2469 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2013 Conference Call (Conference Code: 6632100) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer
PR Newswire - Thu Feb 27, 3:05PM CST
Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a local response rate of 80% has been observed in the 5 evaluable patients with refractory disease, notably 2 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD). These data are consistent with the previously reported positive Phase 1 data in RCWBC.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Monday’s Winners and Losers: Celsion Corporation, Celladon Corp, and Amarin Corporation plc
David Williamson, The Motley Fool - Motley Fool - Mon Feb 24, 8:26PM CST
In this video, Motley Fool health-care analyst David Williamson takes a look at Celsion Corp and Celladon (NASDAQ: CLDN ) as today's two winners in the health-care space, and he also discusses some bad news for Amarin . Celsion has...
Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
PR Newswire - Mon Feb 24, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the Company's planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The trial design is based on a comprehensive analysis of data from the Company's Phase III HEAT Study, which demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment. Celsion expects to launch the study in the first half of 2014.
Future of Costa Rica Oil Refinery Markets to 2020
M2 - Fri Feb 14, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n4jk47/future_of_costa) has announced the addition of the "Future of Costa Rica Oil Refinery Markets to 2020- Outlook of Investments, Business Opportunities, Infrastructure, Petroleum Products, Supply- Demand and Competition" report to their offering. The report provides complete analysis into the Costa Rica refining industry amidst the rapid developments in the recent past. All key trends, drivers and challenges of investing/ entering/ operating in the industry are detailed. Details of all operational and planned refineries including location, start up, operator, owners, constructors, capital investments, project feasibility and configuration are provided in the report. Further, outlook of Crude Distillation Units, Coking Unit Capacity, Fluid Catalytic Cracking Capacity and HydroCracking Unit Capacity are provided to 2020. In addition, business strategies of key refiners in the country along with their net equity weighted primary and secondary unit capacities are provided. It identifies all key investment opportunities in Costa Rica refining market and also analyzes all the upcoming refineries in detail. It updates the major deals and events in the industry from 2012 to 2013. Scope - All potential opportunities and challenges for foreign companies to 2020 - LPG, Gasoline, Diesel, Kerosene production and consumption outlook, 2002- 2020 - Refinery wise CDU, Coking, FCC, HCC Capacity Outlook, 2005- 2020 - Share of the country in Region and Global Refining Capacities, 2013 - Market Drivers, Trends, Outlook and Challenges of operating in refining industry - Refinery details including location, operator, owners, start up, complexity, investment, construction, current status - Business and expansion strategies of leading Refining companies - Profiles of three leading refiners including overview, SWOT, Business description and final analysis - All major oil and gas news, deals and events along with their impact on the industry Reasons to Purchase - Formulate focused investment and development strategies over the next decade - Make strategic and financial decisions based on industry trends and capital expenditure forecasts - Identify key investment opportunities through detailed information on upcoming refineries and capacity information forecasts - Develop clear and complete understanding of the industry through asset by asset historic and forecasted information - Detailed Market Shares, company wise capacities and information on nature of industry allows you to easily beat your competition - Identify the success strategies and financial status of key companies operating in the industry along with their strengths and weaknesses For more information visit http://www.researchandmarkets.com/research/n4...e_of_costa About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
Data on Celsion's ThermoDox - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 4:40PM CST
Celsion announced positive results from the phase III HEAT study on ThermoDox for primary liver cancer.
Celsion plans new study of liver cancer drug
AP - Mon Jan 27, 10:51AM CST
NEW YORK (AP) — Celsion said Monday it wants to start another late-stage clinical trial of its liver cancer drug ThermoDox.
Celsion Corporation Announces Updated Overall Survival Results from Phase III HEAT Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Mon Jan 27, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA), supports the continued clinical development of ThermoDox® in a prospective pivotal Phase III Study, subject to regulatory review and agreement. This analysis followed the announcement on January 31, 2013, that the HEAT Study did not meet its primary endpoint, progression-free survival (PFS). As provided for in the HEAT Study's Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), the Company continues to follow patients for overall survival, the secondary endpoint of the Study. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.
Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Thu May 08, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2014 and provided an update on its development program for ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III program for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver
Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - Thu May 08, 3:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis
Celsion Corporation to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014
PR Newswire - Thu May 01, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss first quarter 2014 financial results at 11:00 a.m. EDT on Thursday, May 8, 2014. To participate in the call, interested parties may dial 1-888-523-1225 (Toll-Free/North America) or 1-719-325-2329 (International/Toll) and ask for the Celsion 1st Quarter 2014 Conference Call (Conference Code: 1639390) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014
PR Newswire - Thu Apr 24, 5:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review of the final study design of the Phase III OPTIMA Study, which both explore ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer, were presented at the 5th European Conference on Interventional Oncology (ECIO) on April 24, 2014 in Berlin, Germany. Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of the Diagnostic Imaging and Intervention at the Pisa University School of Medicine in Italy, former ECIO President, current Chairman of the World Conference on Interventional Oncology (WCIO) and Lead European Principal Investigator for Celsion's clinical studies of ThermoDox® plus RFA, presented the results and review as part of his Honorary Lecture presentation. The slide presentation will be on the Events and Presentations page on the Celsion website when available.
Celsion Announces ThermoDox® HCC Program to be discussed at the 2014 European Conference on Interventional Oncology in Berlin, Germany
PR Newswire - Thu Apr 10, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of the Diagnostic Imaging and Intervention at the Pisa University School of Medicine in Italy, former ECIO President, current Chairman of the World Conference on Interventional Oncology (WCIO) and Lead European Principal Investigator for Celsion's clinical studies of ThermoDox® plus radiofrequency ablation for the treatment of hepatocellular carcinoma (HCC) or primary liver cancer will, in conjunction with his Honorary Lecture presentation, review the final clinical trial results from the 701 patient HEAT Study post hoc analysis and the rationale for the final study design of the Phase III OPTIMA Study at the 5th European Conference on Interventional Oncology, which is being held April 23-26, 2014 in Berlin, Germany.
Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound
PR Newswire - Wed Apr 09, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that data supporting the development of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound (HIFU) were presented on April 5, 2014 at the 14th International Symposium on Therapeutic Ultrasound in Las Vegas, Nevada. In a presentation entitled "Combining Thermosensitive Liposomes with Ultrasound," Mark Dewhirst, D.V.M., Ph.D., the Gustavo S. Montana Professor of Radiation Oncology and Vice Director for Basic Science in the Duke Cancer Institute, presented data demonstrating the potential of ThermoDox plus HIFU to maximize drug delivery to the targeted tumor site. Celsion is exploring the potential of ThermoDox in combination with HIFU as a non-invasive treatment for a variety of cancers, including pancreatic cancer, Glioblastoma Multiforme (GBM), metastatic liver cancer, and breast cancer. Dr. Dewhirst's presentation is available on the Celsion website at www.celsion.com.
Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update
PR Newswire - Thu Mar 13, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
3 Stocks Under $10 Making Big Moves
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
PR Newswire - Thu Mar 06, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2013 financial results at 11:00 a.m. EST on Thursday, March 13, 2014. To participate in the call, interested parties may dial 1-888-572-7033 (Toll-Free/North America) or 1-719-325-2469 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2013 Conference Call (Conference Code: 6632100) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer
PR Newswire - Thu Feb 27, 3:05PM CST
Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a local response rate of 80% has been observed in the 5 evaluable patients with refractory disease, notably 2 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD). These data are consistent with the previously reported positive Phase 1 data in RCWBC.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Monday’s Winners and Losers: Celsion Corporation, Celladon Corp, and Amarin Corporation plc
David Williamson, The Motley Fool - Motley Fool - Mon Feb 24, 8:26PM CST
In this video, Motley Fool health-care analyst David Williamson takes a look at Celsion Corp and Celladon (NASDAQ: CLDN ) as today's two winners in the health-care space, and he also discusses some bad news for Amarin . Celsion has...
Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
PR Newswire - Mon Feb 24, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the Company's planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The trial design is based on a comprehensive analysis of data from the Company's Phase III HEAT Study, which demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment. Celsion expects to launch the study in the first half of 2014.
Future of Costa Rica Oil Refinery Markets to 2020
M2 - Fri Feb 14, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n4jk47/future_of_costa) has announced the addition of the "Future of Costa Rica Oil Refinery Markets to 2020- Outlook of Investments, Business Opportunities, Infrastructure, Petroleum Products, Supply- Demand and Competition" report to their offering. The report provides complete analysis into the Costa Rica refining industry amidst the rapid developments in the recent past. All key trends, drivers and challenges of investing/ entering/ operating in the industry are detailed. Details of all operational and planned refineries including location, start up, operator, owners, constructors, capital investments, project feasibility and configuration are provided in the report. Further, outlook of Crude Distillation Units, Coking Unit Capacity, Fluid Catalytic Cracking Capacity and HydroCracking Unit Capacity are provided to 2020. In addition, business strategies of key refiners in the country along with their net equity weighted primary and secondary unit capacities are provided. It identifies all key investment opportunities in Costa Rica refining market and also analyzes all the upcoming refineries in detail. It updates the major deals and events in the industry from 2012 to 2013. Scope - All potential opportunities and challenges for foreign companies to 2020 - LPG, Gasoline, Diesel, Kerosene production and consumption outlook, 2002- 2020 - Refinery wise CDU, Coking, FCC, HCC Capacity Outlook, 2005- 2020 - Share of the country in Region and Global Refining Capacities, 2013 - Market Drivers, Trends, Outlook and Challenges of operating in refining industry - Refinery details including location, operator, owners, start up, complexity, investment, construction, current status - Business and expansion strategies of leading Refining companies - Profiles of three leading refiners including overview, SWOT, Business description and final analysis - All major oil and gas news, deals and events along with their impact on the industry Reasons to Purchase - Formulate focused investment and development strategies over the next decade - Make strategic and financial decisions based on industry trends and capital expenditure forecasts - Identify key investment opportunities through detailed information on upcoming refineries and capacity information forecasts - Develop clear and complete understanding of the industry through asset by asset historic and forecasted information - Detailed Market Shares, company wise capacities and information on nature of industry allows you to easily beat your competition - Identify the success strategies and financial status of key companies operating in the industry along with their strengths and weaknesses For more information visit http://www.researchandmarkets.com/research/n4...e_of_costa About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
Data on Celsion's ThermoDox - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 4:40PM CST
Celsion announced positive results from the phase III HEAT study on ThermoDox for primary liver cancer.
Celsion plans new study of liver cancer drug
AP - Mon Jan 27, 10:51AM CST
NEW YORK (AP) — Celsion said Monday it wants to start another late-stage clinical trial of its liver cancer drug ThermoDox.
Celsion Corporation Announces Updated Overall Survival Results from Phase III HEAT Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Mon Jan 27, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation (RFA), supports the continued clinical development of ThermoDox® in a prospective pivotal Phase III Study, subject to regulatory review and agreement. This analysis followed the announcement on January 31, 2013, that the HEAT Study did not meet its primary endpoint, progression-free survival (PFS). As provided for in the HEAT Study's Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), the Company continues to follow patients for overall survival, the secondary endpoint of the Study. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.
